Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in Psoriasis

Induction of IL-17+ T Cell Trafficking and Development by IFN- : Mechanism and Pathological Relevance in Psoriasis

(2014) I. Kryczek et al.   JOURNAL OF IMMUNOLOGY

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

(2011) B.E. Strober et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

(2011) A.B. Gottlieb et al.   BRITISH JOURNAL OF DERMATOLOGY

Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab

(2011) Jacqueline M Benson et al.   NATURE BIOTECHNOLOGY

Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells

(2008) Michelle A. Lowes et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET